BioMarin Pharmaceutical Inc
1BMRN
Company Profile
Business description
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Contact
770 Lindaro Street
San RafaelCA94901
USAT: +1 415 506-6700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3,221
Stocks News & Analysis
stocks
ASX utility share downgraded as electricity prices fall
Falling electricity prices weigh on earnings outlook for utility provider.
stocks
Chart of the Week: AI market leader is now surprisingly cheap
This AI beneficiary may still be one of the market’s most compelling bargains.
stocks
Weekly earnings wrap: Rio Tinto leads the way
A closer look at the key earnings results from the first week of August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,452.00 | 42.10 | 0.45% |
| CAC 40 | 8,728.42 | 59.13 | 0.68% |
| DAX 40 | 26,205.40 | 79.10 | 0.30% |
| Dow JONES (US) | 54,164.51 | 184.61 | -0.34% |
| FTSE 100 | 10,883.06 | 5.24 | -0.05% |
| HKSE | 25,530.28 | 385.54 | -1.49% |
| NASDAQ | 26,424.61 | 61.17 | 0.23% |
| Nikkei 225 | 65,683.26 | 617.18 | -0.93% |
| NZX 50 Index | 13,958.06 | 39.12 | -0.28% |
| S&P 500 | 7,727.52 | 3.97 | 0.05% |
| S&P/ASX 200 | 9,271.60 | 41.80 | 0.45% |
| SSE Composite Index | 3,900.35 | 21.92 | 0.57% |